UBS Group AG Buys 187,220 Shares of Cellebrite DI Ltd. $CLBT

UBS Group AG increased its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 99.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 376,376 shares of the company’s stock after purchasing an additional 187,220 shares during the quarter. UBS Group AG owned approximately 0.16% of Cellebrite DI worth $6,786,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. CWM LLC raised its holdings in shares of Cellebrite DI by 85.7% in the 3rd quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after purchasing an additional 720 shares during the period. Advisory Services Network LLC bought a new stake in shares of Cellebrite DI in the 3rd quarter worth approximately $40,000. First Horizon Corp raised its holdings in shares of Cellebrite DI by 421.8% in the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after purchasing an additional 2,337 shares during the period. Vestcor Inc bought a new stake in shares of Cellebrite DI in the 3rd quarter worth approximately $70,000. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Cellebrite DI by 114.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,501 shares of the company’s stock worth $83,000 after purchasing an additional 2,403 shares during the period. Institutional investors own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CLBT. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday. Finally, Needham & Company LLC cut their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, May 15th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $21.75.

Insider Buying and Selling at Cellebrite DI

In other news, CRO Marcus Jewell sold 12,658 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. This represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 13,269 shares of company stock valued at $169,592 over the last quarter. Corporate insiders own 5.70% of the company’s stock.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $13.46 on Wednesday. Cellebrite DI Ltd. has a one year low of $11.02 and a one year high of $19.98. The business has a fifty day moving average price of $13.47 and a 200-day moving average price of $15.45. The firm has a market capitalization of $3.36 billion, a P/E ratio of 48.07, a PEG ratio of 1.63 and a beta of 1.15.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.